GSK bosses will use the results from this latest DREAMM-2 trial as the basis for the regulatory filings.
GlaxoSmithKline PLC (LON:GSK) remains on track to file its multiple myeloma drug with regulators by the end of this year after another successful late-stage clinical trial.
Multiple myeloma is a common blood cancer that is generally considered treatable but not curable. After a while, treatments tend to stop working, which is why companies are trying to come up with new drugs.
In a smaller study earlier this year, called DREAMM-1, almost two-thirds of patients responded positively to the FTSE 100 drugmaker’s belantamab mafodotin proteasome inhibitor.
Data from a second, larger trial, called DREAMM-2, has now come back, which showed the drug achieved a “clinically meaningful” overall response rate in patients who had already been treated with Darzalex – an antibody developed by Belgian pharma giant Jansenn.
“I am pleased with the results of the DREAMM-2 study and excited about what these data could mean for patients with multiple myeloma who have exhausted other lines of treatment,” said chief scientific officer Hal Barron.
“We are on track to file belantamab mafodotin later this year and continue to investigate how it could help even more patients with this disease.”